| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/20/2007 | WO2007105753A1 Triazole derivative or salt thereof |
| 09/20/2007 | WO2007105744A1 Purkinje cell-tropic viral vector |
| 09/20/2007 | WO2007105637A1 Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| 09/20/2007 | WO2007105229A1 Controlled release pharmaceutical composition and process thereof |
| 09/20/2007 | WO2007105177A1 Tetrahydroisoquinoline derivatives to enhance memory function |
| 09/20/2007 | WO2007104959A1 Amino acid derivatives |
| 09/20/2007 | WO2007104933A1 Chemical compounds |
| 09/20/2007 | WO2007104907A1 Improved formulation of comt inhibitors |
| 09/20/2007 | WO2007104775A1 Compounds which inhibit the glycine transporter and uses thereof |
| 09/20/2007 | WO2007104717A1 Quinazolinones and their use as potassium channels activators |
| 09/20/2007 | WO2007104560A1 Substituted 4-amino-quinazoline derivatives as regulators of metabotropic glutamate receptors and their use for producing drugs |
| 09/20/2007 | WO2007104485A2 Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs |
| 09/20/2007 | WO2007104242A1 Compounds capable of inhibiting zinc ion metalloproteinases |
| 09/20/2007 | WO2007090720A3 Use of 2-imidazoles for the treatment of cns disorders |
| 09/20/2007 | WO2007085557A3 Use of substituted 2-imidazole of imidazoline derivatives |
| 09/20/2007 | WO2007080270A3 New cholest-4-en-3-one oxime derivatives, pharmaceutical compositions comprising them, and preparation process |
| 09/20/2007 | WO2007057756B1 Isocystene derivatives for the treatment of pain |
| 09/20/2007 | WO2007041513A3 Conserved membrane activator of calcineurin (cmac), a novel therapeutic protein and target |
| 09/20/2007 | WO2007033193A3 Sustained-release formulation comprising a glucuronate salt of a piperazine compound and uses thereof |
| 09/20/2007 | WO2006017384A3 Indazoles useful in treating cardiovascular diseases |
| 09/20/2007 | WO2005019190A3 (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors |
| 09/20/2007 | WO2004069176A3 Polymer conjugates of mutated neublastin |
| 09/20/2007 | WO2003011823A3 Crfr1 selective ligands |
| 09/20/2007 | US20070219255 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 09/20/2007 | US20070219254 Therapeutic Compounds: Pyridine N-Oxide Scaffold |
| 09/20/2007 | US20070219249 Diarylmethylidene Piperidine Derivatives, Preparations Thereof and Uses Thereof |
| 09/20/2007 | US20070219247 Medicament |
| 09/20/2007 | US20070219233 Substituted Indoles and Their Use as Integrin Antagonists |
| 09/20/2007 | US20070219232 Chemical Compounds |
| 09/20/2007 | US20070219215 Thioamides and Salts Thereof and Cytokine Production Inhibitors Containing Both |
| 09/20/2007 | US20070219209 Piperazine Derivatives Of Alkyl Oxindoles |
| 09/20/2007 | US20070219202 3-(2-alkoxycarbonyl-3-indolyl)-3-oxo-propionic acid ester or propionamide intermediates: methyl 3-[6-fluoro-2-(methoxycarbonyl)-1-methyl-1H-indol-3-yl]-3-oxopropanoate; peripheral neuropathy, Parkinson's disease, Alzheimer's disease |
| 09/20/2007 | US20070219201 Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders |
| 09/20/2007 | US20070219182 1H-2-Benzazepine-1,5(2H)-dione derivatives in which the N is connected via alkylene to a saturated or monounsaterated nitrogen heterocycle, e.g.,2-(3-{4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}propyl)-3,4-dihydro-1H-2-benzazepine-1,5(2H)-dione; dopamine-3 receptor modulators |
| 09/20/2007 | US20070219150 Nerve Cell Differentiation Inducer |
| 09/20/2007 | US20070219130 Administering an effective amount of a SLURP-1 polypeptide of SEQ ID NO: 2; analegsics; neuregulins, promoting the the amplitude of acetylcholine-evoked macroscopic currents; nervous system disorders; neuroprotectants; skindisorders |
| 09/20/2007 | US20070219128 Medical and health-care uses of pufferfish type I collagen extract and processes for producing said extract |
| 09/20/2007 | US20070218137 Sustained release matrix systems for highly soluble drugs |
| 09/20/2007 | US20070218121 Compounds that inhibit caspase activity for treating glaucoma |
| 09/20/2007 | US20070218106 Alcohol Metabolism Moderating Composition |
| 09/20/2007 | US20070218085 Botulinum toxin therapy for neuropsychiatric disorders |
| 09/20/2007 | US20070218037 Therapeutic agent for fibromyalgia |
| 09/20/2007 | US20070218036 Method For The Prevention Of Infection With Nodavirus And Method For The Treatment Thereof |
| 09/20/2007 | US20070218031 Candidate drug which inhibits the interaction between AICD and p53 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease; provides treatment of Alzheimer's disease based on a different Alzheimer's disease onset mechanism from the amyloid hypothesis |
| 09/20/2007 | DE102006011898A1 Medicine that is processed as a combination capsule, useful for the treatment of pain such as headache and migraine, comprises an active substance that is purely of plant origin |
| 09/20/2007 | DE102006011507A1 Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine Drug-loaded nanoparticles based on hydrophilic proteins |
| 09/20/2007 | CA2646256A1 Amino acid derivatives |
| 09/20/2007 | CA2646240A1 Combination therapy for treatment of patients with neurological disorders and cerebral infarction |
| 09/20/2007 | CA2645712A1 Triazole derivative or salt thereof |
| 09/20/2007 | CA2645376A1 Aminoquinolones as gsk-3 inhibitors |
| 09/20/2007 | CA2644368A1 Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| 09/20/2007 | CA2644010A1 Tetrahydroisoquinoline derivatives to enhance memory function |
| 09/20/2007 | CA2643410A1 Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs |
| 09/20/2007 | CA2643222A1 Substituted 4-amino-quinazoline derivatives as regulators of metabotropic glutamate receptors and their use for producing drugs |
| 09/20/2007 | CA2643070A1 Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
| 09/19/2007 | EP1834960A2 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 09/19/2007 | EP1834959A2 Tert-butyl-substituted aromatic steroids having cytoprotective activity |
| 09/19/2007 | EP1834640A2 Kappa opiatagonists for treating bladder diseases |
| 09/19/2007 | EP1833975A2 Regulated expression of transgenes in the central nervous system of mammals |
| 09/19/2007 | EP1833826A2 Tricyclic delta-opioid modulators |
| 09/19/2007 | EP1833825A1 Tricyclic delta-opioid modulators |
| 09/19/2007 | EP1833812A1 N-[(4, 5-diphenyl-3-alkyl-2-thienyl) methyl]amine (amide, sulfonamide, carbamate and urea) derivatives as cannabinoid cb1 receptor antagonists |
| 09/19/2007 | EP1833811A1 Oxygen containing heterocycles as glycine transporter inhibiting compounds |
| 09/19/2007 | EP1833809A1 New benzothiazolecarboxamides |
| 09/19/2007 | EP1833808A1 New benzothiazolesulfonamides |
| 09/19/2007 | EP1833804A1 Aryl sulphonamide modulators |
| 09/19/2007 | EP1833800A1 Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders |
| 09/19/2007 | EP1833797A1 Azacyclic compounds as inhbitors of sensory neurone specific channels (sns) |
| 09/19/2007 | EP1833795A1 Pyridine compounds for the treatment of prostaglandin mediated diseases |
| 09/19/2007 | EP1833570A1 Treatment for severe melancholic depression with epa |
| 09/19/2007 | EP1833478A1 Use of selected cgrp antagonists in combination with other antimigraine medical substances for the treatment of migraine |
| 09/19/2007 | EP1833472A2 Use of certain biphenyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms) |
| 09/19/2007 | EP1833313A2 Compositions containing high omega-3 and low saturated fatty acid levels |
| 09/19/2007 | EP1684702B1 Use of 2-thia-dibenzo[e,h]azulenes for the treatment and prevention of central nervous system diseases and disorders |
| 09/19/2007 | EP1648439A4 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| 09/19/2007 | EP1648433B1 Substituted 2-aminotetralins for the treatment of depressions |
| 09/19/2007 | EP1631298B1 Glycosaminoglycans for treating emotional dysfunctions |
| 09/19/2007 | EP1594836B1 Hydroxy-tetrahydro-naphthalenylurea derivatives |
| 09/19/2007 | EP1572066A4 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2 |
| 09/19/2007 | EP1539115B1 Methods and dosage forms for controlled delivery of paliperidone |
| 09/19/2007 | EP1515975B1 Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
| 09/19/2007 | EP1511719B1 Amide derivatives as inhibitors of the enzymatic activity of renin |
| 09/19/2007 | EP1499605B1 NF-KappaB INHIBITORS |
| 09/19/2007 | EP1496907B1 Tyrosine kinase inhibitors |
| 09/19/2007 | EP1490335B1 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 09/19/2007 | EP1471974B1 Tumor necrosis factor combined with interferon in demyelinating diseases |
| 09/19/2007 | EP1425011A4 Enhancement of learning and memory and treatment of amnesia |
| 09/19/2007 | EP1408911B1 Sustained-release therapeutic bioadhesive systems |
| 09/19/2007 | EP1406605B1 Carbamates of 2-heterocyclic-1,2-ethanediols |
| 09/19/2007 | EP1326990B1 Packaging of positive-strand rna virus replicon particles |
| 09/19/2007 | EP1309590B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 09/19/2007 | EP1255844B1 Humanized anti-ccr2 antibodies and methods of use therefor |
| 09/19/2007 | EP1198456B1 Potassium channel openers |
| 09/19/2007 | EP1192134B1 Processes for the preparation of (r)-g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol |
| 09/19/2007 | EP0883608B1 Optical resolution of methylphenidate by 0,0'-bisaroyl tartaric acids |
| 09/19/2007 | CN101039936A Oxazolo-naphthyl acids as plasminogen activator inhibitor type-1(pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases |
| 09/19/2007 | CN101039911A Polymorph of N,N-diethyl-4-(3-fluorophenyl-piperidin-4-ylidene-methyl)-benzamide hydrochloride salt |
| 09/19/2007 | CN101039910A Donepezil salts suitable for the preparation of pharmaceutical compositions |
| 09/19/2007 | CN101039900A 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 09/19/2007 | CN101039718A Cgrp受体拮抗剂 Cgrp receptor antagonists |